分子吸附再循环治疗慢加急性肝衰竭疗效观察  

Effect of molecular absorbents recirculating system in treatment of acute-on-chronic liver failure

作　　者：王开利[1] 邢汉前[1] 刘俊微[1] 高登莲[1] 赵鸿[1] 张雪华[1] 姚红宇[1] 赵军[1] 

机构地区：[1]解放军第302医院血液净化科,北京100039

出　　处：《胃肠病学和肝病学杂志》2014年第3期333-334,共2页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的观察分子吸附再循环系统(MARS)在慢加急性肝衰竭中的治疗作用。方法比较15例慢加急性肝衰竭患者MARS治疗前后肝、肾功能,血氨、凝血酶原活动度及Glasgow评分等指标。结果 MARS人工肝治疗后,患者体内的血清总胆红素水平较治疗前明显下降,差异有统计学意义(P<0.05)。但血清转氨酶、尿素氮、肌酐、凝血酶原活动度无显著变化(P>0.05),治疗前后Glasgow评分差异无统计学意义(P>0.05)。结论 MARS人工肝是一项安全的治疗措施,其对清除胆红素为代表的蛋白结合毒素效果明显,但并不能改善慢加急性肝衰竭患者肝性脑病的程度及总体预后,其意义在于为肝移植患者赢得时间。Objective To observe the clinical efficiency of molecular absorbents recirculating system （MARS） in treatment of acute-on-chronic liver failure （ACLF）. Methods 15 patients with ACLF received MARS therapy. Clinical data including liver function, renal function, ammonia, prothrombin activity and the Glasgow score were collected and compared before and after the MARS treatment. Results There was statistical difference in the blood bilirubin level before and after MARS treatment. However, the differences in ALT, AST, BUN, creatinine, PTA, prothrombin activi- ty, Glasgow score were not obvious before and after the MARS treatment. No severe side effects were observed during the MARS treatment. Conclusion MARS artificial liver is a safe treatment. Protein-binding toxins like blood bilirubin in the patients could be significantly reduced by the MARS treatment, but the MARS has little effect on treatmente of he- patic encephalopathy in patients with ACLF.

关 键 词：肝脏 肝衰竭 人工肝 分子吸附再循环系统 肝性脑病 

分 类 号：R575.3[医药卫生—消化系统]